

NYRx BLTG Program Update

What Pharmacy Providers and Prescribers Need to Know

Effective **October 12, 2023**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Kombiglyze® XR, Onglyza®, Renvela® powder pack, and Spiriva® HandiHaler®** will be **ADDED** to the program.
- **Firvanq® and Hetlioz® capsule** will be REMOVED from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Flovent® HFA	Rapamune® solution
Alphagan P® 0.15%	Glumetza®	Renvela® powder pack
Amitiza®	Kazano®	Renvela® tablet
Apriso®	Kitabis® Pak	Restasis®
Azopt™	Kombiglyze® XR	Retin-A® cream
Bethkis®	Lialda®	Spiriva® HandiHaler®
Cellcept® suspension	Nesina®	Symbicort®
Ciprodex®	Nexavar®	Tegretol® suspension
Combigan®	Nuvaring®	Tegretol® XR
Concerta®	Onglyza®	Trileptal® suspension
Copaxone® 20mg SQ	Oseni®	Vascepa®
Daytrana®	Pentasa®	Ventolin® HFA
Depakote® Sprinkle	Pradaxa®	Viibryd®
Dexilant®	Protonix® suspension	Zegerid®
Epipen, Epipen JR	Pylera®	

* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Pharmacy Program Preferred Drug List](#)
- [NYRx Education & Outreach Website](#)

Contact Information

The NYRx Education and Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

For NYRx program-related questions and non-member-specific questions, email the NYRx Education and Outreach team at NYRxEO@magellanhealth.com.

The Education and Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.